The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia
| Autor: | Gerard Tobin, Mats Merup, Juhani Vilpo, Karin Karlsson, Göran Roos, Hartmut Döhner, Dirk Kienle, Christer Sundström, Helena Jernberg-Wiklund, Ulf Thunberg, Anna Åleskog, Richard Rosenquist, Anna Laurell, Alexander Kröber, Karin Nilsson, Stephan Stilgenbauer, A Skogsberg |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Cancer Research Chronic lymphocytic leukemia Single-nucleotide polymorphism Biology Cohort Studies Biomarkers Tumor medicine Overall survival Humans Allele Promoter Regions Genetic Gene Aged Retrospective Studies bcl-2-Associated X Protein Aged 80 and over Polymorphism Genetic Promoter Hematology Middle Aged Cell cycle Prognosis medicine.disease Leukemia Lymphocytic Chronic B-Cell Genotype frequency Survival Rate Oncology Cytogenetic Analysis Immunology Cancer research Female |
| Zdroj: | Leukemia. 20:77-81 |
| ISSN: | 1476-5551 0887-6924 |
| Popis: | The G(-248)A polymorphism in the promoter region of the Bax gene was recently associated with low Bax expression, more advanced stage, treatment resistance and short overall survival in B-cell chronic lymphocytic leukemia (CLL), the latter particularly in treated patients. To investigate this further, we analyzed 463 CLL patients regarding the presence or absence of the G(-248)A polymorphism and correlated with overall survival, treatment status and known prognostic factors, for example, Binet stage, VH mutation status and genomic aberrations. In this material, similar allele and genotype frequencies of the Bax polymorphism were demonstrated in CLL patients and controls (n=207), where 19 and 21% carried this polymorphism, respectively, and no skewed distribution of the polymorphism was evident between different Binet stages and VH mutated and unmutated CLLs. Furthermore, no difference in overall survival was shown between patients displaying the G(-248)A polymorphism or not (median survival 85 and 102 months, respectively, P=0.21), and the polymorphism did not influence outcome specifically in treated CLL. Neither did the polymorphism affect outcome in prognostic subsets defined by VH mutation status or genomic aberrations. In conclusion, the pathogenic role and clinical impact of the Bax polymorphism is limited in CLL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|